ABSTRACT

The problem of pharmacotherapy safety for pregnant and lactating women is relevant all over the world. Currently, scientific data on the safety, effectiveness and dosing of drugs for this vulnerable population group is insufficient and treating physicians are forced to make their own decisions about the appropriateness of pharmacotherapy. Pregnant and breastfeeding women are rarely included in clinical trials, making it difficult to obtain up-to-date information about the risks of using medications during these periods in the lives of women and their children. Internationally, there are information resources for medical professionals and consumers that help make clinical decisions for prescription and over-the-counter drugs during pregnancy and lactation in order to reduce the potential risks of pharmacotherapy. Modern pharmacoepidemiological and pharmacokinetic studies of the use of drugs during pregnancy and lactation remain in high demand in the medical community.

ABOUT AUTHOR

LITERATURE

1. Mitchell A.A., Gilboa S.M., Werler M.M., Kelley K.E., Louik C., Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008 // American journal of obstetrics and gynecology. — 2011. — Vol. 205. — Р. 51, e1–8. doi: 10.1016/j.ajog.2011.02.029.
2. Andrade S.E., Gurwitz J.H., Davis R.L. Prescription drug use in pregnancy // Am J Obstet Gynecol. — 2004. — Т. 191. — Р. 398–7. doi: 10.1016/j.ajog.2004.04.025.
3. Mitchell A.A., Hernandez-Diaz S., Louik C., Werler M.M. Medication use in pregnancy // Pharmacoepidemiol Drug Saf. — 2001. — Vol. 10. — Р. 146.
4. Lupattelli A., Spigset O., Twigg M.J., et al. Medication use in pregnancy: a cross-sectional, multinational web-based study//BMJ. — 2014. — Vol. 4. — Р. 004365. doi: 10.1136/bmjopen-2013–004365
5. Glover D.D., Amonkar M., Rybeck B.F., et al. Prescription, over-the-counter, and herbal medicine use in a rural obstetric population//Am. J. Obstet. Gynecol. — 2003. — Vol.188. — Р. 1039–45. doi: 10.1067/mob.2003.223
6. Mazer-Amirshahi M., Samiee-Zafarghandy S, Gray G. et al. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals// Am. J. Obstet. Gynecol. — 2014. — Vol. 211. — Р. 690.e1–11. doi: 10.1016/j.ajog.2014.06.013.
7. Adam M.P., Polifka J.E., Friedman J.M. Evolving knowledge of the teratogenicity of medications in human pregnancy// Am J. Med.. Genet C Semin Med Genet. — 2011. — Т.157. — Р. 175–82. doi: 10.1002/ajmg.c.30313
8. Ayad M., Costantine M.M. Epidemiology of medications use in pregnancy// Semin Perinatol. — 2015. — Nov. — Vol. 39. — № 7. — Р. 508–11. doi: 10.1053/j.semperi.2015.08.002.
9. Schonfeld T., Schmid K.K.., Brown .JS et al. A Pregnancy Testing Policy for Women Enrolled m Clinical Trials// Ethics & Human Research. — 2013. — Т.35. — Р. 9–15. https://www.researchgate.net/publication/259803294_A_pregnancy_testing_policy_for_women_enrolled_in_ clinical_trials
10. Shields K.E., Lyerly A.D. Exclusion of pregnant women from industry-sponsored clinical trials // Obstet. Gynecol.– 2013. — Т. 122. — Р. 1077–81. doi: 10.1097/AOG.0b013e3182a9ca67
11. Hassiotou F., Geddes D. Anatomy of the human mammary gland: current status of knowledge // Clin Anat. — 2013. — Т. 26. — Р. 29–48 https://doi.org/10.1002/ca.22165
12. North K., Gao M., Allen G., Lee A.C. Breastfeeding in a global context: epidemiology, impact, and future directions // Clin Ther. — 2022. — Т. 44. — Р. 228–44. https://doi.org/10.1016/j.clinthera.2021.11.017
13. Maksym K.M, Kalita-Kurzyńska K., Spatz D., Boss M., Collado M.C et al., Development of lactation and breast/chestfeeding adverse event terminology (LaBAET) through a Delphi consensus approach // Int Breastfeed J. — 2025. — Jul 4;20(1). — Р. 53. doi: 10.1186/s13006–025-00743–3
14. Soliman Y., Yakandawala U., Leong C., Garlock E.S., Brinkman F.S.L et al. The use of prescription medications and non-prescription medications during lactation in a prospective Canadian cohort study // Int Breastfeed J. — 2024. — Apr 8. — Р. 19(1):23. doi: 10.1186/s13006–024-00628-x.
15. Eunice Kennedy Shriver National Institute of Child Health and Human Development. List of recommendations from the task force on research specific to pregnant women and lactating women (PRGLAC). — 2019. Available from: https://www.nichd.nih.gov/about/advisory/PRGLAC/recommendations. Cited 2024 Apr 3.
16. Stirland L.E., González-Saavedra L., Mullin D.S., Ritchie C.W., Muniz-Terrera G., Russ T.C. Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice// BMJ. — 2020. — m160. 10.1136/bmj.m160
17. Barnett K. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. // Lancet. — 2012. — Vol. 380. — Р. 37–43. doi: 10.1016/S0140–6736(12)60240–2
18. Subramanian A., Azcoaga-Lorenzo A., Anand A., Phillips K., Lee S.I. Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000–2019 // BMC Med. — 2023. — Jan 16. — Р. 21(1):21. doi: 10.1186/s12916–022-02722–5.
19. Schirm E., Meijer W.M., Tobi H. et al. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system // Eur. J. Obstet. Gynecol. Reprod. Biol. — 2004. — Vol. 114. — Р. 182–188. doi: 10.1016/j.ejogrb.2003.10.024.
20. Ingstrup K.G., Liu X., Gasse C., Debost J.C.P, Munk-Olsen T. Prescription drug use in pregnancy and variations according to prior psychiatric history. Pharmacoepidemiol// Drug Saf. — 2018. Vol. 27. — Р105–113. doi: 10.1002/pds.4355.
21. Cleary B.J. et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women // Pharmacoepidemiol. Drug Saf. — 2010. — Vol. 19. — Р. 408–417. doi: 10.1002/pds.1906
22. Zhang J., Ung C.O.L., Wagner A.K, Guan X., Shi L. Medication use during pregnancy in mainland China: a cross-sectional analysis of a national health insurance database // Clin. Epidemiol. — 2019. — Vol. 11. — Р. 1057–1065. doi: 10.2147/CLEP.S230589
23. SteelFisher G.K., Hero J.O., Caporello H.L., Blendon R.J., Walker W. Obstetrician-Gynecologist Views of Pregnancy-Related Medication Safety // J. Womens Health (Larchmt). — 2020. — Aug; Vol. 29 — № 8. — Р. 1113–1121. Doi: 10.1089/jwh.2019.8007.
24. Lynch M.M., Amoozegar J.B., McClure E.M. et al. Improving safe use of medications during pregnancy: The roles of patients, physicians, and pharmacists // Qual Health Res. — 2017. — Vol. 27. — Р. 2071–2080. Doi.org/10.1177/1049732317732027
25. Lynch M.M., Squiers L.B., Kosa K.M., Dolina S.., Read J.G. et al. Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies // Matern Child Health J. — 2018. — Jan; Vol. 22 — № 1. — Р. 92–100. Doi: 10.1007/s10995–017-2358–0.
26. Sayakhot P., Carolan-Olah M. Internet use by pregnant women seeking pregnancy-related information: A systematic review // BMC Pregnancy Childbirth. — 2016. –Vol. 16. — Р. 65. Doi.org/10.1186/s12884–016-0856–5
27. Bakhireva L.N., Young B.N., Dalen J., Phelan S.T., Rayburn W.F. Patient utilization of information sources about safety of medications during pregnancy// J Reprod Med. — 2011. — Jul-Aug;56(7–8). — Р. 339–43. PMID: 21838165.
28. Kazma J.M., van den Anker J., Allegaert K., Dallmann A.., Ahmadzia HK. Anatomical and physiological alterations of pregnancy // J Pharmacokinet Pharmacodyn. — 2020. — Aug; Vol. 47. — № 4. — Р. 271–285. doi: 10.1007/s10928–020-09677–1. Epub 2020 Feb 6.
29. Waldum H.L., Straume B.K., Lundgren R. Serum group I pepsinogens during pregnancy // Scand. J. Gastroenterol. — 1980. — Vol. 15(1). — Р. 61–63. doi: 10.3109/00365528009181433
30. Qasqas S.A., McPherson C., Frishman W.H., Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation // Cardiol Rev. — 2004. Vol. 12(4). Р. 201–221. doi: 10.1097/01.crd.0000102420.62200.e1.
31. Erman A., Neri A., Sharoni R. et al. Enhanced urinary albumin excretion after 35 weeks of gestation and during labour in normal pregnancy // Scand. J. Clin. Lab. Invest. — 1992. — Vol. 52(5). — Р. 409–413. doi: 10.3109/00365519209088376.
32. Hayashi M., Ueda Y., Hoshimoto K. et al. Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia // Am. J. Kidney Dis. — 2002. — Vol. 39(2). — Р. 392–400. doi: 10.1053/ajkd.2002.30561.
33. Hebert M.F., Easterling T.R., Kirby B. et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study // Clin. Pharmacol. Ther. — 2008. — Vol. 84(2). — Р. 248–253. doi: 10.1038/clpt.2008.1
34. Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N. National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Unit. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy // Am. J. Obstet. Gynecol. — 2005. — Vol. 192(2). — Р. 633–639. doi: 10.1016/j.ajog.2004.08.030.
35. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine // Neurology. — 2004. — Vol. 62(2). — Р. 292–295. doi: 10.1212/01.wnl.0000103286.47129.f8
36. Zhao Y., Alshabi A.M., Caritis S., Venkataramanan R. Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes // Am. J. Obstet. Gynecol. — 2014. Vol. 211(4). — Р. 412.e411–412.e416. doi: 10.1016/j.ajog.2014.03.048.
37. Feghali M., Venkataramanan R., Caritis S. Pharmacokinetics of drugs in pregnancy // Semin Perinatol. — 2015. — Nov;39(7). — Р. 512–9. doi: 10.1053/j.semperi.2015.08.003.
38. Allegaert K., van Mieghem T., Verbesselt R. et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy // Am. J. Obstet. Gynecol. — 2009. Vol. 200(2). — Р. 170.e171–170.e177. doi: 10.1016/j.ajog.2008.08.067.
39. Muller A.E., Mouton J.W., Oostvogel P.M. et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period // Antimicrob. Agents Chemother. — 2010. — Vol. 54(5). — Р. 2175–2181. doi: 10.1128/AAC.01017–09.
40. Joshi A.A., Vaidya S.S., St-Pierre M.V. et al. Placental ABC Transporters: Biological Impact and Pharmaceutical Significance // Pharm. Res. — 2016. — Vol. 33. — Р. 2847–2878. 10.1007/s11095–016-2028–8
41. Pacifici G.M., Nottoli R. Placental Transfer of Drugs Administered to the Mother // Clin Pharmacokinet. — 1995. — Vol. 28. — Р. 235–269. Doi:10.2165/00003088–199528030-00005
42. Jovanovic L., Pettitt D.J. Treatment with insulin and its analogs in pregnancies complicated by diabetes // Diabetes Care. — 2007. — Р. 30: Doi: 10.2337/dc07-s220
43. Broussard C.S., Frey M.T., Hernandez-Diaz S., Greene M.F., Chambers C.D. et al. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention — convened meeting // Am. J. Obstet. Gynecol. — 2014. — Sep. — Vol. 211. — № 3. — Р. 208–214 doi: 10.1016/j.ajog.2014.05.040.
44. Temming L.A., Cahill A.G., Riley L.E. Clinical management of medications in pregnancy and lactation // Am. J. Obstet. Gynecol. — 2016. — Jun;214(6). — Р. 698–702. doi: 10.1016/j.ajog.2016.01.187.
45. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/